Ladan Amin

Ladan Amin

Auto-generated profile, based on publicly available information

Ladan Amin

Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
LALadan Amin
Ladan Amin
DHDavid A. Harris
David A. Harris
Several cell-surface receptors for neurotoxic forms of amyloid-β (Aβ) have been described, but their molecular interactions with Aβ assemblies and their relative contributions to mediating Alzheimer’s disease pathology have remained uncertain. Here, we used super-resolution microscopy to directly visualize Aβ-receptor interactions at the nanometer scale. We report that one documented Aβ receptor, PrPC, specifically inhibits the polymerization of Aβ fibrils by binding to the rapidly growing end of each fibril, thereby blocking polarized elongation at that end. PrPC binds neurotoxic oligomers and protofibrils in a similar fashion, suggesting that it may recognize a common, end-specific, structural motif on all of these assemblies. Finally, two other Aβ receptors, FcγRIIb and LilrB2, affect Aβ fibril growth in a manner similar to PrPC. Our results suggest that receptors may trap Aβ oligomers and protofibrils on the neuronal surface by binding to a common molecular determinant on these assemblies, thereby initiating a neurotoxic signal.

15 October 2016 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
LALadan Amin
Ladan Amin
XNXuan T. A. Nguyen
Xuan T. A. Nguyen
IRIrene Giulia Rolle
Irene Giulia Rolle
EDElisa D'ESte
Elisa D'ESte
GGGabriele Giachin
Gabriele Giachin
Giuseppe LegnameGiuseppe Legname
Giuseppe Legname
The cellular prion protein (PrPC), encoded by the PRNP gene, is a ubiquitous glycoprotein, which is highly expressed in the brain. This protein, mainly known for its role in neurodegenerative diseases, is involved in several physiological processes including neurite outgrowth. By using a novel focal stimulation technique, we explored the potential function of PrPC, in its soluble form, as a signaling molecule. Thus, soluble recombinant prion proteins (recPrP) encapsulated in micro-vesicles were released by photolysis near the hippocampal growth cones. Local stimulation of wild-type growth cones with full-length recPrP induced neurite outgrowth and rapid growth cone turning towards the source. This effect was shown to be concentration dependent. Notably, PrPC-knockout growth cones were insensitive to recPrP stimulation, but this property was rescued in PrP-knockout growth cones expressing GFP–PrP. Taken together, our findings indicate that recPrP functions as a signaling molecule, and that its homophilic interaction with membrane-anchored PrPC might promote neurite outgrowth and facilitate growth cone guidance.

12 July 2021 in Journal of Extracellular Vesicles
Verified
Journal Article
Open access
PDF file
GDGiulia D’Arrigo
Giulia D’Arrigo
Martina GabrielliMartina Gabrielli
Martina Gabrielli
FSFederica Scaroni
Federica Scaroni
PSPaolo Swuec
Paolo Swuec
LALadan Amin
Ladan Amin
CFChiara Fenoglio
Chiara Fenoglio
Astrocytes‐derived extracellular vesicles (EVs) are key players in glia‐neuron communication. However, whether EVs interact with neurons at preferential sites and how EVs reach these sites on neurons remains elusive. Using optical manipulation to study single EV‐neuron dynamics, we here show that large EVs scan the neuron surface and use neuronal processes as highways to move extracellularly. Large EV motion on neurites is driven by the binding of EV to a surface receptor that slides on neuronal membrane, thanks to actin cytoskeleton rearrangements. The use of prion protein (PrP)‐coated synthetic beads and PrP knock out EVs/neurons points at vesicular PrP and its receptor(s) on neurons in the control of EV motion. Surprisingly, a fraction of large EVs contains actin filaments and has an independent capacity to move in an actin‐mediated way, through intermittent contacts with the plasma membrane. Our results unveil, for the first time, a dual mechanism exploited by astrocytic large EVs to passively/actively reach target sites on neurons moving on the neuron surface.

26 November 2021 in Science Advances
Verified
Journal Article
Open access
LLLuise Linsenmeier
Luise Linsenmeier
BMBehnam Mohammadi
Behnam Mohammadi
MSMohsin Shafiq
Mohsin Shafiq
KFKarl Frontzek
Karl Frontzek
JBJulia Bär
Julia Bär
MGMarkus Glatzel
Markus Glatzel
Ligand-stimulated enzymatic release or cellular degradation of PrP may interfere with neurodegeneration-associated toxicity.

29 October 2019 in bioRxiv
Verified
Preprint
Open access
PDF file
LALadan Amin
Ladan Amin
DHDavid A. Harris
David A. Harris
Oligomeric forms of amyloid-β (Aβ) peptide are known to be the primary neurotoxic species in Alzheimer’s disease (AD), but how they interact with neurons to produce their deleterious effects is unclear. Over ten different cell-surface receptors for Aβ have been described, but their molecular interactions with Aβ assemblies and their relative contributions to mediating AD pathology have remained uncertain. In the present work, we have used super-resolution microscopy to directly visualize Aβ-receptor interactions at the nanometer scale. We report that one documented Aβ receptor, the cellular prion protein, PrPC, specifically inhibits the polymerization Aβ fibrils via a unique mechanism in which it binds specifically to the rapidly growing end of each fibril, thereby blocking polarized elongation at that end. PrPC binds neurotoxic oligomers and protofibrils in a similar fashion, suggesting that it may recognize a common, end-specific, structural motif on all of these assemblies. Finally, two other candidate Aβ receptors, FcγRIIb and LilrB2, affect Aβ fibril growth in a manner similar to PrPC. Taken together, our results suggest that neurotoxic signaling by several different receptors may be activated by common molecular interactions with both fibrillar and oligomeric Aβ ligands. Targeting such interactions with small molecules represents an attractive therapeutic strategy for treatment of AD.